Getein Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	1,027	1,149	1,355	1,816	1,398	1,120
Other Revenue	15.58	15.58	14.45	6.18	3.62	3.73
Revenue	1,043	1,165	1,369	1,822	1,402	1,123
Revenue Growth (YoY)	-16.46%	-14.93%	-24.85%	29.98%	24.78%	16.02%
Cost of Revenue	340.88	374.39	479.71	671.56	485.42	414.42
Gross Profit	701.79	790.41	889.45	1,150	916.29	708.92
Selling, General & Admin	334.77	371.6	439.87	407.26	324.08	258.6
Research & Development	170.39	181.21	217.99	223.22	163.39	119.07
Other Operating Expenses	21.07	3.17	0.14	-0.07	12.55	11.27
Operating Expenses	566.18	569.68	677.22	653.29	506.69	401.43
Operating Income	135.61	220.73	212.24	497.01	409.59	307.49
Interest Expense	-11.93	-14.93	-16.94	-16.61	-14.31	-6.22
Interest & Investment Income	42.99	45.79	72.02	45.5	47.97	35.49
Currency Exchange Gain (Loss)	5.8	5.8	11.31	19.41	-0.97	-9.64
Other Non Operating Income (Expenses)	-3.22	-0.49	-0.54	-3.29	-4.42	-6.49
EBT Excluding Unusual Items	169.26	256.9	278.09	542.03	437.86	320.63
Impairment of Goodwill	-25.83	-25.83	-	-	-	-
Gain (Loss) on Sale of Investments	15.31	0.15	10.25	18.46	-4.29	24.41
Gain (Loss) on Sale of Assets	2.8	1.59	0.67	0.02	0.95	0.57
Asset Writedown	26.61	-5.32	-1.69	-0.53	-	-
Other Unusual Items	25.93	25.93	17.63	-	17.11	28.43
Pretax Income	214.08	253.43	304.94	559.98	451.63	374.04
Income Tax Expense	15.91	23.55	20.86	56.03	39.62	43.73
Earnings From Continuing Operations	198.17	229.88	284.08	503.94	412.01	330.31
Minority Interest in Earnings	10.59	-6.24	-4.31	-5.03	-13.02	-25.58
Net Income	208.76	223.64	279.77	498.91	398.99	304.73
Net Income to Common	208.76	223.64	279.77	498.91	398.99	304.73
Net Income Growth	-7.68%	-20.06%	-43.92%	25.04%	30.93%	-10.29%
Shares Outstanding (Basic)	509	508	509	509	505	508
Shares Outstanding (Diluted)	509	508	509	509	512	508
Shares Change (YoY)	1.16%	-0.08%	-0.08%	-0.48%	0.72%	-0.82%
EPS (Basic)	0.41	0.44	0.55	0.98	0.79	0.60
EPS (Diluted)	0.41	0.44	0.55	0.98	0.78	0.60
EPS Growth	-8.74%	-20.00%	-43.88%	25.64%	30.00%	-9.54%
Free Cash Flow	185.61	266.6	75.09	265.51	252.77	71.94
Free Cash Flow Per Share	0.36	0.53	0.15	0.52	0.49	0.14
Dividend Per Share	0.180	0.180	0.200	0.340	0.243	0.184
Dividend Growth	-5.26%	-10.00%	-41.18%	39.98%	32.30%	-10.04%
Gross Margin	67.31%	67.86%	64.96%	63.14%	65.37%	63.11%
Operating Margin	13.01%	18.95%	15.50%	27.28%	29.22%	27.37%
Profit Margin	20.02%	19.20%	20.43%	27.38%	28.46%	27.13%
Free Cash Flow Margin	17.80%	22.89%	5.49%	14.57%	18.03%	6.40%
EBITDA	221.77	306.61	297.73	561.95	457.04	343.42
EBITDA Margin	21.27%	26.32%	21.75%	30.84%	32.61%	30.57%
D&A For EBITDA	86.16	85.88	85.49	64.93	47.44	35.93
EBIT	135.61	220.73	212.24	497.01	409.59	307.49
EBIT Margin	13.01%	18.95%	15.50%	27.28%	29.22%	27.37%
Effective Tax Rate	7.43%	9.29%	6.84%	10.01%	8.77%	11.69%
Revenue as Reported	1,043	1,165	1,369	1,822	1,402	1,123
Advertising Expenses	-	20.46	43.56	47.32	36.19	38.44

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.